Bayer (BAYRY)
(Delayed Data from OTC)
$8.09 USD
+0.35 (4.52%)
Updated Aug 1, 2025 03:59 PM ET
2-Buy of 5 2
A Value D Growth A Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BAYRY 8.09 +0.35(4.52%)
Will BAYRY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BAYRY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BAYRY
Regeneron Stock Rises on Q2 Earnings and Sales Beat, Eylea HD Sales Up
INCY's Q2 Earnings & Revenues Beat Estimates on Higher Product Sales
BAYRY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Do Q2 Reports Shape a More Uncertain Outlook?
SRPT Slides on Voluntary US Elevidys Shipment Pause Amid Scrutiny
Best Value Stocks to Buy for July 22nd
Other News for BAYRY
Bayer gains after raising 2025 outlook
Regeneron posts Q2 beat as new Eylea version outperforms
EU pharma lobby criticizes potential Trump tariffs on pharmaceuticals
Bayer says FDA extends review period for elinzanetant NDA
Bayer's elinzanetant review period gets extended by FDA